Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
Authors:
- Lorenza PecciariniLPLorenza Pecciarini
- Emanuela BrunettoEBEmanuela Brunetto
- Greta GrassiniGGGreta Grassini
- Valeria De PascaliVPValeria De Pascali
- Francesca Rita OgliariFOFrancesca Rita Ogliari
- Anna TalaricoATAnna Talarico
- Giovanna MarraGMGiovanna Marra
- Gilda MagliacaneGMGilda Magliacane
- Miriam RedegalliMRMiriam Redegalli
- Gianluigi ArrigoniGAGianluigi Arrigoni
- Chiara LazzariCLChiara Lazzari
- Vanesa GregorcVGVanesa Gregorc
Open Access
Abstract
The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.Keywords
This publication has 23 references indexed in Scilit:
- Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assaysGenes, Chromosomes and Cancer, 2019
- RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesCancers, 2019
- Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patientsLung Cancer, 2019
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyArchives of Pathology & Laboratory Medicine, 2018
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Fluorescence In situ Hybridization: Cell-Based Genetic Diagnostic and Research ApplicationsFrontiers in Cell and Developmental Biology, 2016
- Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnosticsOncotarget, 2015
- Anchored multiplex PCR for targeted next-generation sequencingNature Medicine, 2014
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase InhibitorsThe Journal of Molecular Diagnostics, 2013
- Targeted Resequencing RevealsALKFusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four MethodsBioMed Research International, 2013